Impact of Modifiable Risk Factors on Long-Term Outcomes after Coronary Artery Bypass Surgery
Background Risk factors control and secondary prevention measures are often reported to be suboptimal in patients undergoing coronary artery bypass grafting (CABG) and may lead to worse clinical outcomes. We aimed to examine potentially modifiable risk factors in patients undergoing CABG and investigate their association with long-term coronary events.
Methods Cardiovascular risk factors were recorded preoperatively in the setting of a cardiac catheterization laboratory and were analyzed in relation to long-term coronary events, defined as acute coronary syndrome (ACS) or revascularization after CABG.
Results Study population included 1,125 patients undergoing CABG without previous revascularization. Modifiable risk factors included hypertension (71%), hyperlipidemia (67%), diabetes (42%), obesity (28%), and smoking (21%). Only 8% did not have any of the five risk factors. During the mean follow-up of 93 ± 52 months after CABG, 179 patients (16%) experienced a coronary event. Incidence rates were higher in patients with than without the presence of each of the modifiable risk factors, except obesity. Active smoking (hazard ratio [HR]: 1.51; 95% confidence interval [CI]: (1.07–2.13); p = 0.020), presence of diabetes (HR: 1.61; 95% CI: 1.18–2.18; p = 0.002), and hyperlipidemia (HR: 2.13; 95% CI: 1.45–3.14; p < 0.001) were independent predictors of future coronary events after CABG; they also displayed a progressive stepwise increment in the risk of long-term coronary events when cumulatively present.
Conclusions In patients undergoing CABG, diabetes, hyperlipidemia, and smoking, as documented preoperatively, were potentially modifiable risk factors that were independently and cumulatively associated with long-term risk of ACS or coronary revascularization, highlighting the importance of early identification and risk factors control for improving cardiovascular health after CABG.
Keywordscoronary artery bypass graft surgery - acute coronary syndrome - risk factors - coronary revascularization - secondary prevention
Eingereicht: 24. August 2020
Angenommen: 21. September 2020
01. Dezember 2020 (online)
© 2020. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
- 1 ElBardissi AW, Aranki SF, Sheng S, O'Brien SM, Greenberg CC, Gammie JS. Trends in isolated coronary artery bypass grafting: an analysis of the Society of Thoracic Surgeons adult cardiac surgery database. J Thorac Cardiovasc Surg 2012; 143 (02) 273-281
- 2 Cornwell LD, Omer S, Rosengart T, Holman WL, Bakaeen FG. Changes over time in risk profiles of patients who undergo coronary artery bypass graft surgery: the Veterans Affairs Surgical Quality Improvement Program (VASQIP). JAMA Surg 2015; 150 (04) 308-315
- 3 Mehta RH, Bhatt DL, Steg PG. et al; REACH Registry Investigators. Modifiable risk factors control and its relationship with 1 year outcomes after coronary artery bypass surgery: insights from the REACH registry. Eur Heart J 2008; 29 (24) 3052-3060
- 4 Goyal A, Alexander JH, Hafley GE. et al; PREVENT IV Investigators. Outcomes associated with the use of secondary prevention medications after coronary artery bypass graft surgery. Ann Thorac Surg 2007; 83 (03) 993-1001
- 5 Escaned J. Secondary revascularization after CABG surgery. Nat Rev Cardiol 2012; 9 (09) 540-549
- 6 Williams JB, Delong ER, Peterson ED, Dokholyan RS, Ou FS, Ferguson Jr TB. Society of Thoracic Surgeons and the National Cardiac Database. Secondary prevention after coronary artery bypass graft surgery: findings of a national randomized controlled trial and sustained society-led incorporation into practice. Circulation 2011; 123 (01) 39-45
- 7 O'flaherty M, Sans-Menendez S, Capewell S, Jorgensen T. Epidemiology of atherosclerotic cardiovascular disease: scope of the problem and its determinants. In: Gielen S, De Backer G, Piepoli M, Wood D. eds. The ESC Textbook of Preventive Cardiology. 1st ed.. Oxford: Oxford University Press; 2015
- 8 Yusuf S, Hawken S, Ounpuu S. et al; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364 (9438): 937-952
- 9 Piepoli MF, Hoes AW, Agewall S. et al; ESC Scientific Document Group. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016; 37 (29) 2315-2381
- 10 Sousa-Uva M, Neumann FJ, Ahlsson A. et al; ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur J Cardiothorac Surg 2019; 55 (01) 4-90
- 11 Ortega FB, Lavie CJ, Blair SN. Obesity and cardiovascular disease. Circ Res 2016; 118 (11) 1752-1770
- 12 Benedetto U, Danese C, Codispoti M. Obesity paradox in coronary artery bypass grafting: myth or reality?. J Thorac Cardiovasc Surg 2014; 147 (05) 1517-1523
- 13 Jin R, Grunkemeier GL, Furnary AP, Handy Jr JR. Is obesity a risk factor for mortality in coronary artery bypass surgery?. Circulation 2005; 111 (25) 3359-3365
- 14 Zafrir B, Salman N, Crespo-Leiro MG. et al; Heart Failure Long-Term Registry Investigators. Body surface area as a prognostic marker in chronic heart failure patients: results from the Heart Failure Registry of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2016; 18 (07) 859-868
- 15 Catapano AL, Graham I, De Backer G. et al; ESC Scientific Document Group. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 2016; 37 (39) 2999-3058
- 16 Fulcher J, O'Connell R, Voysey M. et al; Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 2015; 385 (9976): 1397-1405
- 17 Kulik A, Ruel M. Lipid-lowering therapy and coronary artery bypass graft surgery: what are the benefits?. Curr Opin Cardiol 2011; 26 (06) 508-517
- 18 Barakat AF, Saad M, Abuzaid A, Mentias A, Mahmoud A, Elgendy IY. Perioperative statin therapy for patients undergoing coronary artery bypass grafting. Ann Thorac Surg 2016; 101 (02) 818-825
- 19 Saxena A, Shan L, Reid C. et al. Impact of smoking status on early and late outcomes after isolated coronary artery bypass graft surgery. J Cardiol 2013; 61 (05) 336-341
- 20 Chow CK, Jolly S, Rao-Melacini P, Fox KA, Anand SS, Yusuf S. Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes. Circulation 2010; 121 (06) 750-758
- 21 Griffo R, Ambrosetti M, Tramarin R. et al; ICAROS investigators. Effective secondary prevention through cardiac rehabilitation after coronary revascularization and predictors of poor adherence to lifestyle modification and medication. Results of the ICAROS Survey. Int J Cardiol 2013; 167 (04) 1390-1395
- 22 Aronson D, Edelman ER. Role of CABG in the management of obstructive coronary arterial disease in patients with diabetes mellitus. Curr Opin Pharmacol 2012; 12 (02) 134-141
- 23 Orbach A, Halon DA, Jaffe R. et al. Impact of diabetes and early revascularization on the need for late and repeat procedures. Cardiovasc Diabetol 2018; 17 (01) 25
- 24 Lloyd-Jones DM, Hong Y, Labarthe D. et al; American Heart Association Strategic Planning Task Force and Statistics Committee. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic Impact Goal through 2020 and beyond. Circulation 2010; 121 (04) 586-613
- 25 Aneni EC, Crippa A, Osondu CU. et al. Estimates of mortality benefit from ideal cardiovascular health metrics: a dose response meta-analysis. J Am Heart Assoc 2017; 6 (12) e006904